In This Article:
Investing.com - U.S. and European health officials are investigating big-selling heartburn treatment Zantac and generics of the drug after a carcinogen was discovered in low levels, Bloomberg first reported Friday.
The drug ranitidine, branded as Zantac, was found to contain levels of a probable carcinogen in testing by an online pharmacy. The same contaminant prompted a recall of blood-pressure pills last year.
"The FDA is evaluating whether the low levels of (the contaminant) NDMA in ranitidine pose a risk to patients," the regulator said. It added that it is not recommending patients stop taking the medication at this time.
Sanofi (PA:SASY), the maker of Zantac, fell 0.8% in Paris trading. Its ADRs (NASDAQ:SNY) lost 0.3%.
Related Articles
Fannie, Freddie regulator revises caps on multifamily loans
London Stock Exchange flatly rejects Hong Kong's $39 billion takeover offer
U.S. appeals court rules against Trump in foreign payments case